Mekky, M., Helal, M., NasrEldin, E., Osman, A. (2021). Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 11(1), 39-43. doi: 10.21608/aeji.2020.46609.1108
Mohamed A Mekky; Mohamed S Helal; Eman NasrEldin; Ashraf M Osman. "Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients". Afro-Egyptian Journal of Infectious and Endemic Diseases, 11, 1, 2021, 39-43. doi: 10.21608/aeji.2020.46609.1108
Mekky, M., Helal, M., NasrEldin, E., Osman, A. (2021). 'Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients', Afro-Egyptian Journal of Infectious and Endemic Diseases, 11(1), pp. 39-43. doi: 10.21608/aeji.2020.46609.1108
Mekky, M., Helal, M., NasrEldin, E., Osman, A. Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2021; 11(1): 39-43. doi: 10.21608/aeji.2020.46609.1108
Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients
1Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University,Egypt.
2Department of Clinical Pathology, Faculty of Medicine, Assiut University,Egypt.
Abstract
Background and study aim: The real life effect of anti-HCV direct acting agents (DAAs) on the hematologic profile and serum levels of vitamin B12 and folic acid was not yet fully studied. Patients and Methods: Between March 2018 and March 2019, a prospective study was designed at El-Rajhi University Hospital, Egypt, to randomly select HCV-related child A cirrhosis that were eligible for DAAs. All patients received oral sofosbuvir (SOF; 400 mg) plus daclatasvir (DCV; 60 mg) once daily plus weight based ribavirin (RBV): 1,000 mg/day if < 75 kg and 1,200 mg/day if ≥75 kg; regimen for 12 weeks. Hematologic profile, folic acid and B12 levels were assessed twice; before the start of therapy and at the end of week12 by electrochemiluminescence immune-assay. Results: A total of 25 patients were enrolled (age 50.11 ± 7.89 years, 15 males). The majority had no co morbidities. Hematologic profile in pre and post therapy showed significant decrease in hemoglobin levels after treatment (13.1 ± 0.93 Vs 11.15 ± 0.90, respectively; p=0.02). Folic acid level showed a significant decrease (14.56 ± 4.45 Vs 9.06 ± 2.11; respectively, p=0.01) and vitamin B12 levels showed a minor increase (345.09 ± 55.98 Vs 355.19 ± 33.45; respectively, p=0.08). Conclusion: Significant changes in the kinetics of B12 and folic acid were reported during the course of DAAs in management of chronic HCV with cirrhosis. Further large cohort and randomized controlled trial needed to study the effect of add-on these vitamins on the response rates.
View on SCiNiTO
Top